Interacting Drugs |
Efavirenz, emtricitabine, and tenofovir vs CYP2B6 Inhibitors (Strong) |
Security Level |
 |
Mechanism |
CYP2B6 Inhibitors (Strong): May decrease the metabolism of CYP2B6 Substrates. |
Management |
Consider therapy modification |
Efavirenz, emtricitabine, and tenofovir vs CYP2B6 Inhibitors (Strong)
Post Review about Efavirenz, emtricitabine, and tenofovir vs CYP2B6 Inhibitors (Strong) Click here to cancel reply.
Other Interactions of Efavirenz, emtricitabine, and tenofovir
Other Interactions of CYP2B6 Inhibitors (Strong)
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.